
|Videos|May 16, 2022
Novel Agents Under Evaluation for HER2+ Breast Cancer and Brain Metastases
A look at exciting clinical trials enrolling patients with HER2+ breast cancer and leptomeningeal disease, a previously unheard-of opportunity.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
4
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
5



























































